Welcome to LookChem.com Sign In|Join Free

CAS

  • or

701213-36-7

Post Buying Request

701213-36-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1-BENZOYL-4-[[4-METHOXY-7-(3-METHYL-1H-1,2,4-TRIAZOL-1-YL)-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]OXOACETYL]PIPERAZINE

    Cas No: 701213-36-7

  • No Data

  • 1 Gram

  • Metric Ton/Day

  • Afine Chemicals Limited
  • Contact Supplier

701213-36-7 Usage

Description

BMS 626529 is an inhibitor of HIV-1 attachment. It binds to non-ligand bound HIV-1 gp120 to inhibit HIV-1 interaction with host CD4+ T cells and subsequent HIV-1 binding and cell entry. BMS 626529 reduces infectivity of laboratory strains and clinical isolates of HIV-1 (EC50s = 0.4-2,000 and 25-2,000 nM, respectively) with cytotoxic concentration (CC50) values greater than 100 μM in a panel of mammalian cell lines.

Uses

Temsavir is a Fostemsavir (CAS# 864953-29-7) intermediate and an antiviral agent. It is an HIV-1 attachment inhibitor.

in vitro

the activity of bms-626529 is virus dependent, due to heterogeneity within gp120. bms-626529 had half-maximal effective concentration values of6 log10, with half-maximal effective concentration values in the low pm range against the most susceptible viruses. measurement of the binding affinity of bms-626529 for purified gp120 suggests that a contributory factor to its inhibitory potency may be a relatively long dissociative half-life [1].

references

[1] nowicka-sans b, gong yf, mcauliffe b, dicker i, ho ht, zhou n, eggers b, lin pf, ray n, wind-rotolo m, zhu l, majumdar a, stock d, lataillade m, hanna gj, matiskella jd, ueda y, wang t, kadow jf, meanwell na, krystal m. in vitro antiviral characteristics of hiv-1 attachment inhibitor bms-626529, the active component of the prodrug bms-663068. antimicrob agents chemother. 2012;56(7):3498-507. [2] nettles re, schürmann d, zhu l, stonier m, huang sp, chang i, chien c, krystal m, wind-rotolo m, ray n, hanna gj, bertz r, grasela d. pharmacodynamics, safety, and pharmacokinetics of bms-663068, an oral hiv-1 attachment inhibitor in hiv-1-infected subjects. j infect dis. 2012;206(7):1002-11.

Check Digit Verification of cas no

The CAS Registry Mumber 701213-36-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,1,2,1 and 3 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 701213-36:
(8*7)+(7*0)+(6*1)+(5*2)+(4*1)+(3*3)+(2*3)+(1*6)=97
97 % 10 = 7
So 701213-36-7 is a valid CAS Registry Number.

701213-36-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione

1.2 Other means of identification

Product number -
Other names CS-0938

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:701213-36-7 SDS

701213-36-7Relevant articles and documents

Synthetic method of compound with anti-HIV activity

-

, (2018/10/27)

The invention discloses a synthetic method of a compound Fostemsavir (BMS-663068) with anti-HIV activity. The synthesis route is novel; the steps are short; the reaction yield is high; the productioncost is low; and the practical value and the social economical benefit are high.

Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies

Fox, Richard J.,Tripp, Jonathan C.,Schultz, Mitchell J.,Payack, Joseph F.,Fanfair, Dayne D.,Mudryk, Boguslaw M.,Murugesan, Saravanababu,Chen, Chung-Pin H.,La Cruz, Thomas E.,Ivy, Sabrina E.,Broxer, Sévrine,Cullen, Ryan,Erdemir, Deniz,Geng, Peng,Xu, Zhongmin,Fritz, Alan,Doubleday, Wendel W.,Conlon, David A.

, p. 1095 - 1109 (2017/08/23)

The development of two enabling routes that led to the production of >1000 kg of BMS-663068 (3) is described. The route identified for the initial 100 kg delivery to support development activities and initial clinical trials involved the conversion of 2-amino-4-picoline to the parent active pharmaceutical ingredient (API), followed by pro-drug installation and deprotection. To eliminate the problematic isolation of the parent API and synthesis of di-t-butyl(chloromethyl)phosphate, a second-generation pro-drug installation route was developed which involved the conversion of a late-stage common intermediate to an N(1)-thioether derivative followed by chloromethylation, displacement with di-t-butylpotassium phosphate, and deprotection. This second strategy resulted in the multikilogram scale preparation of the API in 14 linear steps and ~7% overall yield.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 701213-36-7